Invus Financial Advisors’s Unity Biotechnology UBX Stock Holding History

Invus Financial Advisors’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-109,500	Closed	-$1.6M	–	9
2021 Q4	$1.6M	Hold	109,500	–	–	0.49%	8
2021 Q3	$3.29M	Hold	109,500	–	–	0.88%	8
2021 Q2	$5.08M	Hold	109,500	–	–	1.01%	8
2021 Q1	$6.57M	Hold	109,500	–	–	1.51%	7
2020 Q4	$5.74M	Hold	109,500	–	–	2.4%	6
2020 Q3	$3.79M	Sell	109,500 -109,500	-50%	-$6.93M	1.82%	6
2020 Q2	$19M	Hold	219,000	–	–	6.87%	6
2020 Q1	$12.7M	Hold	219,000	–	–	6.24%	5
2019 Q4	$15.8M	Buy	+219,000	New	+$15.5M	8.01%	5

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Invus Financial Advisors's UBX Position: Q1 2022 in Review

Invus Financial Advisors sold out of Unity Biotechnology (UBX) in Q1 2022, closing a stake of 109,500 shares — an estimated $1.6M sold.

Invus Financial Advisors first reported a position in UBX in Q4 2019 and held it in 9 quarters. The position peaked at $19M in Q2 2020. 70 funds tracked by Wall St. Rank hold UBX as of Q1 2022.

Invus Financial Advisors reported no remaining Unity Biotechnology position as of Q1 2022 after selling out during the quarter.
Invus Financial Advisors sold 109,500 Unity Biotechnology shares in Q1 2022, an estimated $1.6M.
Invus Financial Advisors first reported a position in Unity Biotechnology in Q4 2019 and held it in 9 quarters.
Invus Financial Advisors's Unity Biotechnology position peaked at $19M in Q2 2020.
70 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2022.

Based on Invus Financial Advisors's 13F filing for Q1 2022, filed 16 May 2022.